Your browser doesn't support javascript.
loading
Structural basis of species-selective antagonist binding to the succinate receptor.
Haffke, Matthias; Fehlmann, Dominique; Rummel, Gabriele; Boivineau, Jacques; Duckely, Myriam; Gommermann, Nina; Cotesta, Simona; Sirockin, Finton; Freuler, Felix; Littlewood-Evans, Amanda; Kaupmann, Klemens; Jaakola, Veli-Pekka.
Affiliation
  • Haffke M; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. matthias.haffke@novartis.com.
  • Fehlmann D; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. matthias.haffke@novartis.com.
  • Rummel G; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Boivineau J; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Duckely M; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Gommermann N; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Cotesta S; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Sirockin F; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Freuler F; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Littlewood-Evans A; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Kaupmann K; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Jaakola VP; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. klemens.kaupmann@novartis.com.
Nature ; 574(7779): 581-585, 2019 10.
Article in En | MEDLINE | ID: mdl-31645725
The tricarboxylic acid cycle intermediate succinate is involved in metabolic processes and plays a crucial role in the homeostasis of mitochondrial reactive oxygen species1. The receptor responsible for succinate signalling, SUCNR1 (also known as GPR91), is a member of the G-protein-coupled-receptor family2 and links succinate signalling to renin-induced hypertension, retinal angiogenesis and inflammation3-5. Because SUCNR1 senses succinate as an immunological danger signal6-which has relevance for diseases including ulcerative colitis, liver fibrosis7, diabetes and rheumatoid arthritis3,8-it is of interest as a therapeutic target. Here we report the high-resolution crystal structure of rat SUCNR1 in complex with an intracellular binding nanobody in the inactive conformation. Structure-based mutagenesis and radioligand-binding studies, in conjunction with molecular modelling, identified key residues for species-selective antagonist binding and enabled the determination of the high-resolution crystal structure of a humanized rat SUCNR1 in complex with a high-affinity, human-selective antagonist denoted NF-56-EJ40. We anticipate that these structural insights into the architecture of the succinate receptor and its antagonist selectivity will enable structure-based drug discovery and will further help to elucidate the function of SUCNR1 in vitro and in vivo.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Biphenyl Compounds / Receptors, G-Protein-Coupled Limits: Animals / Humans Language: En Journal: Nature Year: 2019 Type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Biphenyl Compounds / Receptors, G-Protein-Coupled Limits: Animals / Humans Language: En Journal: Nature Year: 2019 Type: Article Affiliation country: Switzerland